Min Xia

Dec 5, 2024 | cell.com | Yusuke Isshiki |Xi Chen |Matt Teater |Ioannis Karagiannidis |Winson Cai |Cem Meydan | +18 more

KeywordsEZH2T cell immunotherapyCAR-Tbispecific antibodiesfollicular lymphomaDLBCLGet full text accessLog in, subscribe or purchase for full access. References1. Schuster, S.J. ∙ Svoboda, J. ∙ Chong, E.A. ... Chimeric Antigen Receptor T Cells in Refractory B-Cell LymphomasN. Engl. J. Med. 2017; 377:2545-25542. Locke, F.L. ∙ Miklos, D.B. ∙ Jacobson, C.A. ... Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell LymphomaN. Engl. J. Med. 2022; 386:640-6543. Bishop, M.R. ∙ Dickinson, M. ∙ Purtill, D. ...

Jul 21, 2024 | nature.com | Min Xia |Yan Liu

AbstractMetabolic dysfunction-associated fatty liver disease (MAFLD) is a growing threat leading to substantial disease burden globally. Poor sleep and physical inactivity are common in modern societies and independently associated with MAFLD, however, their joint effects on MAFLD remains unclear. This population-based cross-sectional study was conducted in Xinjiang Uygur Autonomous Region, China, between July 2019 and September 2021.

Feb 10, 2024 | dx.doi.org | Yu ZHANG |Min Xia |Hongwei Song |Minghui Yang

Download Hi-Res ImageDownload to MS-PowerPointCite This:J. Phys. Chem. A 2024, XXXX, XXX Terms & Conditions Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses).